

### **Morbidity and Mortality Rates in Patients with Ankylosing Spinal Disorders Comparing Between Single-Level, Multi-Level, and Spinopelvic Injuries**

*Eli W. Bunzel, MD; Celeste Tավոlаrо, MD; Conоr P. Kleweno, MD; Richard Bransford, MD; Carlo Bellabarba, MD; Jonathan Yamaguchi*

**Purpose:** Patients with ankylosing spine disorders (ASDs), such as ankylosing spondylitis (AS) and diffuse idiopathic skeletal hyperostosis (DISH), have a fourfold fracture risk during their lifetime as compared with the general population. Patients with spine fractures and ASDs are at high risk for complications and death. The goal of the study was to assess the morbidity and mortality rates associated with a single-level spine fracture, multi-level spine fractures, or the combination of spine and pelvis fractures.

**Methods:** We conducted a retrospective cohort review of a large consecutive series of adult patients with ASDs from 2005 to 2020 at a Level I trauma center. Demographic data, procedural data, hospital data, and 90-day postoperative data were obtained. Statistical analyses compared single-level, multi-level, and spinopelvic injuries groups using Fisher's exact test and analysis of variance to compare categorical and continuous variables, respectively.

**Results:** 383 cases of ASDs (155 AS and 228 DISH) with fractures were identified from 2005 to 2020. There were 323 patients with a single-level injury, 45 with multi-level injury, and 15 with spinopelvic injuries. There were 57 deaths within 90 -days (14.9%), but no difference in mortality between groups ( $P = 0.949$ ). There were 96 patients (25.1%) with complications. The most common complications were wound infection 52 (13.6%), pulmonary complications 38 (9.9%), and hardware-related 7 (1.9%). Complication rates in these 3 groups were significantly different for infection (single-level 11.5%, multi-level 26.7%, and spinopelvic 20%, respectively,  $P = 0.015$ ). Significant differences among the groups were identified for ASD type, surgical invasiveness index, energy of mechanism, injury location, instrumented levels, estimated blood loss, and discharge disposition ( $P < 0.05$ ).

**Conclusion:** The overall 90-day mortality rate was 14.9%, not significantly different between groups. The overall complication rate in the treatment of ASD patients is 25.1%. The complication rate is significantly higher in patients with multi-level injury and in patients with a combination of spine and pelvic fractures.

**Table 1:** Comparison of Patient Variables

|                             |   | Single          | Multi             | Spinopelvic      | p-value |
|-----------------------------|---|-----------------|-------------------|------------------|---------|
|                             | Total N                                   | 323             | 45                | 15               |         |
| <b>Demographics</b>         | Age (years, mean ± SD)                    | 70.61 ± 13.40   | 68.18 ± 12.89     | 63 ± 11.20       | 0.059   |
|                             | BMI (kg/m <sup>2</sup> , mean ± SD)       | 31.88 ± 7.65    | 31.56 ± 7.78      | 30.6 ± 6.87      | 0.799   |
|                             | Sex (% Female)                            | 45 (13.9%)      | 9 (20.0%)         | 1 (6.7%)         | 0.417   |
|                             | ASD Type (% AS)                           | 128 (39.6%)     | 25 (55.6%)        | 2 (13.3%)        | 0.011*  |
|                             | Follow-up (days, mean ± SD)               | 147.52 ± 228.79 | 274.56 ± 527.93   | 117.13 ± 130.39  | 0.014*  |
| <b>Comorbidities</b>        | Diabetes                                  | 109 (33.7%)     | 14 (31.1%)        | 4 (26.7%)        | 0.889   |
|                             | Hypertension                              | 190 (58.8%)     | 29 (64.4%)        | 7 (46.7%)        | 0.468   |
|                             | ASA Class                                 |                 |                   |                  | 0.174   |
|                             | I: No Disturbance                         | 2 (0.6%)        | 0                 | 0                |         |
|                             | II: Mild Disturbance                      | 44 (13.6%)      | 4 (8.9%)          | 3 (20.0%)        |         |
|                             | III: Severe Disturbance                   | 180 (55.7%)     | 32 (71.1%)        | 8 (53.3%)        |         |
|                             | IV: Life Threatening                      | 97 (30.0%)      | 8 (17.8%)         | 4 (26.7%)        |         |
|                             | V: Moribund                               | 0               | 1 (2.2%)          | 0                |         |
| Surgical Invasiveness Index | 12.61 ± 4.57                              | 23.78 ± 7.71    | 12.73 ± 5.66      | <0.001*          |         |
| <b>Injury</b>               | Energy of Mechanism (% Low Energy)        | 187 (57.9%)     | 19 (42.2%)        | 3 (20.0%)        | 0.003*  |
|                             | Injury Location                           |                 |                   |                  | <0.001* |
|                             | C/CT                                      | 124 (38.4%)     | 30 (66.7%)        | 0                |         |
|                             | T/TL                                      | 184 (57.0%)     | 8 (17.8%)         | 0                |         |
|                             | L/LP                                      | 15 (4.6%)       | 0                 | 0                |         |
|                             | Multi                                     | 0               | 7 (15.6%)         | 15 (100%)        |         |
| <b>Operative</b>            | Surgical Approach                         |                 |                   |                  | 0.498   |
|                             | Posterior                                 | 312 (96.6%)     | 43 (95.6%)        | 14 (93.3%)       |         |
|                             | Anterior                                  | 3 (0.9%)        | 0                 | 0                |         |
|                             | Both                                      | 8 (2.5%)        | 2 (4.4%)          | 1 (6.7%)         |         |
|                             | Instrumented Levels                       | 5.93 ± 1.76     | 11.11 ± 3.65      | 6.27 ± 2.49      | <0.001* |
|                             | Estimated Blood Loss                      | 567.71 ± 541.11 | 1167.78 ± 1037.32 | 1006.67 ± 963.23 | <0.001* |
| <b>Hospital Variables</b>   | Length of ICU Stay (days, mean ± SD)      | 6.17 ± 14.29    | 8.04 ± 9.44       | 10.87 ± 8.24     | 0.319   |
|                             | Length of Hospital Stay (days, mean ± SD) | 14.49 ± 20.65   | 15.80 ± 11.00     | 21.40 ± 12.92    | 0.388   |

Data represented as N (%) or mean ± SD unless otherwise specified.  
 \* denotes significance, p<0.05

POSTER ABSTRACTS

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device they wish to use in clinical practice.